“…Nedaplatin, a platinum-based agents, is approved in several countries, and its efficacy and safety in patients with ovarian cancer has been reported ( Michikami et al, 2013 ). Previous reports have demonstrated the efficacy of desensitization therapy with carboplatin, cisplatin, and oxaliplatin ( Cakmak et al, 2021 , Takase et al, 2015 ). However, to the best of our knowledge, nedaplatin desensitization therapy for patients with PSR ovarian cancer has never been reported.…”